ARQT vs. AGIO

Last updated Apr 2, 2026

Compare and contrast key facts about Arcutis Biotherapeutics, Inc. (ARQT) and Agios Pharmaceuticals, Inc. (AGIO).

Performance

ARQT vs. AGIO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and Agios Pharmaceuticals, Inc. (AGIO). The values are adjusted to include any dividend payments, if applicable.

ARQT vs. AGIO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ARQT Arcutis Biotherapeutics, Inc.	-17.01%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	29.04%
AGIO Agios Pharmaceuticals, Inc.	25.61%	-17.16%	47.55%	-20.69%	-14.57%	-24.14%	-11.08%

Fundamentals

Market Cap ARQT : $3.27B AGIO : $1.99B
EPS ARQT : -$0.12 AGIO : -$7.10
PS Ratio ARQT : 8.45 AGIO : 36.79
PB Ratio ARQT : 17.25 AGIO : 1.67
Total Revenue (TTM) ARQT : $376.07M AGIO : $54.03M
Gross Profit (TTM) ARQT : $339.38M AGIO : $47.68M
EBITDA (TTM) ARQT : -$1.11M AGIO : -$438.48M

Returns By Period

In the year-to-date period, ARQT achieves a -17.01% return, which is significantly lower than AGIO's 25.61% return.

ARQT

• 1D: 2.29%
• 1M: -2.67%
• YTD: -17.01%
• 6M: 21.96%
• 1Y: 60.88%
• 3Y*: 29.88%
• 5Y*: -4.12%
• 10Y*: —

AGIO

• 1D: 1.06%
• 1M: 17.09%
• YTD: 25.61%
• 6M: -14.67%
• 1Y: 24.78%
• 3Y*: 14.18%
• 5Y*: -8.26%
• 10Y*: -2.00%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ARQT vs. AGIO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARQT

ARQT Risk / Return Rank: 72
ARQT Sharpe Ratio Rank: 74
ARQT Sortino Ratio Rank: 74
ARQT Omega Ratio Rank: 69
ARQT Calmar Ratio Rank: 72
ARQT Martin Ratio Rank: 72

AGIO

AGIO Risk / Return Rank: 54
AGIO Sharpe Ratio Rank: 53
AGIO Sortino Ratio Rank: 53
AGIO Omega Ratio Rank: 66
AGIO Calmar Ratio Rank: 48
AGIO Martin Ratio Rank: 48

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARQT vs. AGIO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Agios Pharmaceuticals, Inc. (AGIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARQT	AGIO	Difference
Sharpe ratio Return per unit of total volatility	1.02	0.35	+0.67
Sortino ratio Return per unit of downside risk	1.85	0.93	+0.91
Omega ratio Gain probability vs. loss probability	1.22	1.20	+0.02
Calmar ratio Return relative to maximum drawdown	1.69	0.33	+1.36
Martin ratio Return relative to average drawdown	3.97	0.70	+3.27
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARQT vs. AGIO - Sharpe Ratio Comparison

The current ARQT Sharpe Ratio is 1.02, which is higher than the AGIO Sharpe Ratio of 0.35. The chart below compares the historical Sharpe Ratios of ARQT and AGIO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ARQT	AGIO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.02	0.35	+0.67
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.06	-0.14	+0.09
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.03	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.02	0.01	+0.01

Correlation

The correlation between ARQT and AGIO is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ARQT vs. AGIO - Dividend Comparison

Neither ARQT nor AGIO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ARQT vs. AGIO - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, which is greater than AGIO's maximum drawdown of -87.36%. Use the drawdown chart below to compare losses from any high point for ARQT and AGIO.

Drawdown Indicators

	ARQT	AGIO	Difference
Max Drawdown Largest peak-to-trough decline	-95.02%	-87.36%	-7.66%
Max Drawdown (1Y) Largest decline over 1 year	-31.99%	-50.89%	+18.90%
Max Drawdown (5Y) Largest decline over 5 years	-94.71%	-72.16%	-22.55%
Max Drawdown (10Y) Largest decline over 10 years	—	-82.86%	—
Current Drawdown Current decline from peak	-34.83%	-74.68%	+39.85%
Average Drawdown Average peak-to-trough decline	-50.46%	-58.57%	+8.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.63%	23.81%	-10.18%

Volatility

ARQT vs. AGIO - Volatility Comparison

Arcutis Biotherapeutics, Inc. (ARQT) and Agios Pharmaceuticals, Inc. (AGIO) have volatilities of 15.32% and 15.62%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARQT	AGIO	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.32%	15.62%	-0.30%
Volatility (6M) Calculated over the trailing 6-month period	43.81%	79.68%	-35.87%
Volatility (1Y) Calculated over the trailing 1-year period	60.16%	71.01%	-10.85%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.95%	57.37%	+14.58%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.53%	57.30%	+20.23%

Financials